Contracts › 75A50125C00008
75A50125C00008: Osivax - Clinical Proof of Concept of OVX836, a Single-Shot Broadly Protective Influenza a Vaccine for Immediate Protection Against Emerging Pandemic Strains
Awarded to Osivax by Office of Assistant Secretary for Preparedness and Response.
$19.5Mobligated
$98.6Mpotential value
24 July 2028current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75A50125C00008 |
|---|---|
| Awardee | Osivax |
| Awarding agency | Office of Assistant Secretary for Preparedness and Response |
| Awarding office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN11 Health R&D Services; Health Care Services; Basic Research |
| Offers received | 1 |
| Period of performance | 25 July 2025 to 24 July 2028 |
| Potential end | 24 July 2028 |
| Estimated recompete solicitation | ~Q1 2028 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record